9. Tecentriq

tecentriq

Active ingredient: atezolizumab
Disease: cancer
Peak annual sales estimate: $2.5 billion
Approved: May 18
Company: Roche

The scoop: Roche bagged a quick approval for the first-ever PD-L1 medalthough it lags a few years behind the PD-1 checkpoint inhibitors from Merck and Bristol-Myers Squibbwhen in May, it got the FDA green light for type of bladder cancer called urothelial carcinoma. But it is lining up more lucrative indicationsnotably gunning for a non-small cell lung cancer license in the hope of beating out Opvido and Keytruda. -- Ben Adams

9. Tecentriq
Read more on

Suggested Articles

Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.

In this week's EuroBiotech Report, Healx raises $56 million, Boehringer's VC wing backs anti-cancer virus startup and Ipsen bags Blueprint drug.

In our EuroBiotech roundup this week, GammaDelta forms antibody spinout, gene therapy startup raises cash and Amsterdam plans medical business park.